372results about "Peptide libraries" patented technology

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

The invention relates to a method for producing nano-arrays and micro-arrays. The method described herein provides a method of generating an array of spatially separated proteins. The method relies on covalently attaching each of a plurality of proteins to a structured nucleic acid particle (SNAP) and attaching the SNAP to a solid support.

Disclosed are fusion proteins (and homodimers and heterodimers thereof). Fusion proteins can bind to a protein of interest and to an internalizing receptor (transferrin receptor) on a cell surface. Once bound, the protein of interest can be internalized and / or degraded inside a cell.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

Methods for preparing a personalized cancer vaccine and a method to train a machine learning HLA-peptide presentation prediction model. Further wherein, a method of making a HLA class II tetramer or multimer comprising an epitope, the method comprising contacting a purified soluble HLA-DM loaded with a peptide epitope with a HLA class II tetramer or multimer, thereby forming a HLA class II tetramer or multimer loaded with the peptide epitope, is disclosed.

An object of the present invention is to provide methods of discovering drugs effective for tough targets, which have conventionally been discovered only with difficulty. The present invention relates to novel methods for cyclizing peptide compounds, and novel peptide compounds and libraries comprising the same, to achieve the above object.

PURPOSE: To provide a biochip and a manufacturing method for the same.SOLUTION: A detection unit of a biochip includes a substrate, a first insulating layer, a semiconductor layer, a second insulating layer, a first metal layer, a second metal layer, and a protection layer. The semiconductor layer includes a reaction region. The second insulating layer is disposed on the semiconductor layer, and includes a first part, a second part, and a first opening part for exposing the reaction region. The first metal layer is disposed on the second part and includes a source, a drain, a gate, and a first wall structure. The second metal layer includes a second wall structure disposed on the first wall structure. The protection layer is disposed on the first metal layer and the second metal layer. The protection layer includes a second opening part, a third opening part, and a fourth opening part, and includes a flat part that defines the second opening part by surrounding it, a first projection part that defines the third opening part by surrounding it, and a second projection part that defines the fourth opening by surrounding it. In a normal direction of the substrate, the first opening part, the second opening part, the third opening part, and the fourth opening part overlap with each other.SELECTED DRAWING: Figure 4

Disclosed are fusion proteins (homodimers and heterodimers thereof). Fusion proteins that can bind to a protein of interest that is a G Protein-Coupled Receptor (GPCR) and to an internalizing receptor on a cell surface (transferrin receptor). Once bound, the protein of interest can be internalized and / or degraded inside a cell.

A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and / or (ii) the amino acid residue at position 89 is T; and / or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.

The present invention relates to a bicyclic peptide complex comprising a peptide construct, the construct comprising: (i) a polypeptide having a free terminus (N or C); (ii) optionally a nucleic acid encoding the polypeptide; and (iii) a dyad-symmetric linker (TSL) compound attached to the polypeptide, wherein the linker is attached to the terminus of the polypeptide and to at least two distinct side chains of the peptide via a covalent bond. The present invention also relates to a library and methods for making the complex, and to screening methods using the same.

The present invention relates to an anti-IL-8 antibody. Specifically, the present invention provides an antibody heavy chain variable region, wherein the heavy chain variable region includes the following three complementary determining regions (CDRs): CDR1 as shown in SEQ ID NO: 1, CDR2 as shown in SEQ ID NO: 2, and CDR3 as shown in SEQ ID NO: 3. The antibody of the present invention can bind to IL-8 with high affinity and block or inhibit IL-8-induced activities, such as pro-inflammatory activity, chemotactic activity and angiogenesis, to treat immune, autoimmune, inflammatory or infectious diseases and cancers associated with IL-8.

The present invention provides a vector construct comprising an open reading frame including a nucleic acid sequence encoding a modified pIX filamentous phage coat protein in which the methionine (M) residue at position 1 of the pIX filamentous phage coat protein has been replaced with an alternative amino acid residue. Also provided are phage particles or phage display systems comprising the vector construct, as well as methods and kits for phage display.

To provide a method for introducing a nucleic acid into a floating cell.SOLUTION: The present invention provides a method for introducing nucleic acids into non-adherent cells, comprising the step of contacting nucleic acids with non-adherent cells in solutions comprising dextran derivatives having average molecular weights greater than 70kDa.SELECTED DRAWING: None

To provide an amino acid capable of improving the membrane permeability of peptide compounds, as well as a peptide compound including the amino acid.SOLUTION: The present invention provides an amino acid having a side chain capable of forming at least one intramolecular hydrogen bond.SELECTED DRAWING: None

The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (BBB), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.

The present invention provides a method of constructing a library of binder scaffolds (library of protein scaffolds) comprising the steps a) providing an initial polypeptide, wherein said initial polypeptide comprises or consists of a polypeptide having at least 90% identity to SEQ ID NO:1, and b) introducing diversity into copies of said initial polypeptide to form the binder scaffold library (protein scaffold library).

The invention discloses DNA (deoxyribonucleic acid) coupled non-natural amino acid as well as a synthesis method and application thereof. The synthesis method of the DNA coupled non-natural amino acid comprises the following steps: adding inorganic alkali and 2, 5-dibromohexane diamide into a boric acid buffer solution containing DNA coupled cysteine as shown in a general formula (I) in the specification, adding an organic phase, and reacting at 25-37 DEG C to enable the DNA coupled cysteine to be subjected to desulfurization elimination, thereby obtaining the DNA coupled non-natural amino acid. DNA coupling dehydroalanine shown as a general formula (II) in the specification is obtained; the method comprises the following steps: carrying out nucleophilic addition reaction on DNA coupled dehydroalanine and a nucleophilic reagent under an alkaline condition or carrying out dipolar cycloaddition reaction on DNA coupled dehydroalanine and 2, 5-substituted tetrazole under an ultraviolet condition to obtain the DNA coupled unnatural amino acid. By adopting the method, the integrity of the DNA chain can be effectively ensured, no by-product is generated in the reaction, and a more powerful chemical tool is provided for construction and subsequent modification of a DNA coding molecular library.

This invention provides a novel masked antibody. The masked antibody is a molecule that binds to a target antigen, which comprises a moiety binding to a target antigen, a first peptide recognizing a target antigen-binding site comprised in such moiety, and a second peptide comprising an amino acid sequence cleaved by a protease, wherein, after the second peptide is cleaved by a protease, the molecule has higher binding intensity to the target antigen, compared with that before it is cleaved.

The present disclosure relates to a modified polypeptide of glutamine synthetase having enhanced activity and a method of producing L-glutamine using the same. Since production of L-glutamine may be increased by using the novel modified polypeptide without a decrease in a growth rate compared to wild-type strains having glutamine synthetase activity, the modified polypeptide may be widely used for mass production of L-glutamine.

Disclosed is a peptide-immobilized bead library from which peptides are more likely to be obtained as candidates of useful substances such as pharmaceuticals, and with which the amino acid sequence bound to a target substance can be more easily analyzed, compared to known OPOB libraries. The peptide-immobilized bead library has a structure of General Formula [I]. In General Formula [I], X is an amino acid residue; n is an integer of 4 to 8; Y is a cyclization structure; A is a spacer structure; B is a specific cleavage site-containing structure; and the 4 to 8 amino acid residues of X are each independently randomly selected.

The present invention relates to methods for producing recombinant binding proteins with binding specificity for peptide-MHC (pMHC) complexes. The invention also relates to recombinant binding proteins with binding specificity for pMHC complexes, which comprise one, two or more designed repeat domains, preferably designed ankyrin repeat domains, and to such binding proteins which further comprise a binding factor with binding specificity for a protein expressed on the surface of immune cells, preferably T cells. In addition, the invention relates to nucleic acids encoding such binding proteins or repeat domains, pharmaceutical compositions comprising such binding proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, including cancer, infectious diseases and autoimmune diseases.

The present invention provides a cyclic peptide compound optionally linked to a nucleic acid, the cyclic peptide compound having a cyclic moiety wherein: (1) the cyclic moiety is composed of 13 or 14 amino acid residues; (2) among the amino acid residues constituting the cyclic moiety, the number of N-substituted amino acid residues is 7 or more, the number of amino acid residues in a single side chain is 3 or fewer, and the number of native amino acid residues is 4 or fewer; and (3) the ClogP / total amide bond (ClogP / total AB) is 1.0 to 1.8.

Described herein are VHH antibody libraries with heavy chain variable domain framework scaffolds that have complementarity determining regions (CDRs) found in naturally occurring human antibodies, and methods for making such antibody libraries. The antibody libraries do not include members that contain one or more liabilities that affect one or more properties of the members.

The present invention relates to a method of selecting a polypeptide for display on a genetic display system according to activity, comprising the steps of: displaying the polypeptide on the genetic display system, screening a system for binding to a target, and selecting a member binding to the target; cloning a nucleic acid encoding the polypeptide from a member of the display system, and expressing the nucleic acid in an expression system to produce the polypeptide, or sequencing the polypeptide from a member of the display system, and cloning and expressing the polypeptide or a library of polypeptides using synthesis-based DNA; and determining the activity of the polypeptide in an assay.

Use of a compound, microarray chip substrate, microarray chip and use and method thereof. The present application provides use of a compound, or a geometric isomer, tautomer, isotopically labeled, hydrate, solvate or salt thereof in chip surface modification. Also provided is a microarray chip substrate modified by the compound, and a microarray chip comprising the microarray chip substrate. The microarray chip substrate of the present application can greatly improve the surface modification function by surface modification, improve nucleic acid synthesis yield, amplify detection signal, and avoid non-specificity and cross-talk. It has a wide application prospect.

A method for generating a plurality of neoantigens from a sample obtained from a patient, comprising the steps of: - sequencing the DNA and / or RNA from the sample; - identifying a number of DNA and / or RNA variants from the sequencing data; - identifying from said plurality of DNA and / or RNA variants those which give rise to qualitative differences in the corresponding encoded peptides and / or those which give rise to the generation of novel peptide sequences; and generating said plurality of neoantigens, wherein each neoantigen contains one of said identified differences in said encoded peptide.

This disclosure relates to reversible affinity selection methods useful for the isolation and enrichment of covalent peptide inhibitors directly from large synthetic peptide libraries. Also disclosed herein are synthetic peptides for targeting HPV16 E6 and peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 protein.

The present invention provides a method for constructing a cyclic compound library that overcomes the limitations of conventional ring-closing methods for cyclic compound libraries, has the advantages of milder ring-closing reaction conditions and high generality, can be used to construct monocyclic and bicyclic compound libraries, and involves few side reactions. [Solution] A cyclic compound library and its construction method are provided, which uses a solid support, a molecule containing a photocleavable group, a linker, a building block, a ring-closing A-terminal molecule, and a ring-closing B-terminal molecule at both ends of the reaction synthesis, and utilizes the decomposition of the solid support under light irradiation to complete ring closure of the amino acid residue structures of the ring-closing A-terminal molecule A and the ring-closing B-terminal molecule B through the action of cyclohydrolase. This method, which uses mild ring closure conditions, is more universal and expands the types of chemical reactions and the diversity of the encoded compound library.